{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:17:14Z","timestamp":1788891434272,"version":"build-2803163510"},"reference-count":0,"publisher":"Dermsquared","issue":"4","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Online J"],"abstract":"<jats:p>Sarcoidosis is a chronic multisystemic, inflammatory disease characterized by the formation of noncaseating granulomas, with cutaneous involvement in a fraction of patients. Although existing literature reports dupilumab to cause sarcoidosis-like reactions, we present a 57-year-old man with erythrodermic sarcoidosis and atopic dermatitis refractory to numerous systemic medications that later improved with dupilumab. The improvement of his pruritus and cutaneous lesions after dupilumab initiation, followed by worsening after temporary discontinuation, then re-improvement after re-initiation supported dupilumab\u2019s therapeutic role. IL-4 and IL-13 stimulate tissue fibrosis and irreversible tissue damage in sarcoidosis, perhaps explaining dupilumab\u2019s therapeutic mechanism in this patient\u2019s case. For patients with severe sarcoidosis refractory to numerous medications, clinicians should keep in mind dupilumab as a potential option, particularly for those patients with concomitant atopic dermatitis.<\/jats:p>","DOI":"10.25251\/btwtbw27","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:09:40Z","timestamp":1761268180000},"source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab treatment for pruritus-associated cutaneous sarcoidosis"],"prefix":"10.25251","volume":"31","author":[{"given":"Sooin","family":"Choi","sequence":"first","affiliation":[{"name":"College of Human Medicine, Michigan State University, Grand Rapids, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Pandher","sequence":"additional","affiliation":[{"name":"Department of Dermatology,  Henry Ford Health, Detroit, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology,  Henry Ford Health, Detroit, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Dermatology,  Henry Ford Health, Detroit, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"53906","published-online":{"date-parts":[[2025,9,8]]},"container-title":["Dermatology Online Journal"],"original-title":[],"link":[{"URL":"https:\/\/doj.dermsquared.com\/index.php\/doj\/article\/download\/219\/44","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/doj.dermsquared.com\/index.php\/doj\/article\/download\/219\/44","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:57:23Z","timestamp":1772657843000},"score":1,"resource":{"primary":{"URL":"https:\/\/doj.dermsquared.com\/index.php\/doj\/article\/view\/219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,8]]}},"URL":"https:\/\/doi.org\/10.25251\/btwtbw27","relation":{},"ISSN":["1087-2108"],"issn-type":[{"value":"1087-2108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}